Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.18

€1.18

-4.340%
-0.052
-4.340%
€3.26
 
19.06.24 / Tradegate WKN: A2PLTK / Symbol: PSNL / Name: Personalis / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Personalis Inc Stock

Personalis Inc took a tumble today and lost -€0.052 (-4.340%).
We see a rather positive sentiment for Personalis Inc with 8 Buy predictions and 1 Sell predictions.
With a target price of 3 € there is potential for a 155.32% increase which would mean more than doubling the current price of 1.18 € for Personalis Inc.
Our community identified positive and negative aspects for Personalis Inc stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Personalis Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Personalis Inc in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Personalis Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Personalis Inc -4.340% -7.843% -12.313% -37.500% -43.510% -94.499% -
Stoke Therapeutics Inc -2.900% -12.500% -5.674% - - - -
Immuron -5.100% -3.627% -7.000% 14.815% 11.377% -51.309% -

Comments

Prediction Buy
Perf. (%) -
Target price 3.272
Change
Ends at 21.06.25

Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Ratings data for PSNL provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -31.34%
Target price 3.253
Change
Ends at 09.05.25

Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Ratings data for PSNL provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -14.42%
Target price 3.744
Change
Ends at 30.04.25

Personalis, Inc. (NASDAQ: PSNL) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $4.00 price target on the stock.
Ratings data for PSNL provided by MarketBeat
Show more

News

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring


Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT